KUALA LUMPUR, April 12 (Bernama) -- Rundo International Pharmaceutical Research & Development Co., Ltd. (Rundo) has selected eClinical solutions from OmniComm Systems, Inc., to set up industry-leading early phase clinics and deliver top service.
Under the terms of two separate agreements, Rundo will use OmniComm’s TrialMaster EDC and TrialOne for research.
Rundo’s customers in China include domestic and multinational companies, with research ranging from Phase I through IV clinical trials.
The Shanghai-based company selected OmniComm’s solutions for its availability of mature and validated systems, multiple therapeutic areas of experience, support of industry standards and competitive pricing.
Additionally, the solutions provide market-leading technology for early phase research and Phase II-IV studies.
In compliance with global industry standards, TrialMaster allows user organisations to ensure the quality and integrity of data collected and managed during an entire set of studies.
TrialMaster also enables users to comply with China’s FDA (NMPA) regulations and approval process for new drugs and comply with regulations from the US FDA and the EMA.
On the other hand, TrialOne reduces timelines and costs through faster and more directed volunteer recruitment, easy-to-build schedule-based workflows, real-time Bedside Data Collection, direct data capture from devices and automated processing of laboratory samples.
OmniComm Systems is a leading strategic software solutions provider, offering eClinical solutions for clinical research with an extensive global experience from more than 6,000 clinical trials.
More details at www.omnicomm.com
-- BERNAMA
No comments:
Post a Comment